Measurement of Varicella-Zoster Virus (VZV)-specific cell-mediated immunity: Comparison between VZV skin test and interferon-γ enzyme-linked immunospot assay

Journal of Infectious Diseases

Volumn 198, Issue 9, 2008, Pages 1327-1333

  Sadaoka, Kay ^a   Okamoto, Shigefumi ^a   Gomi, Yasuyuki ^b   Tanimoto, Takeshi ^b   Ishikawa, Toyokazu ^b   Yoshikawa, Tetsushi ^c   Asano, Yoshizo ^c   Yamanishi, Koichi ^a   Mori, Yasuko ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b Osaka University   (Japan)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CHICKENPOX VACCINE; GAMMA INTERFERON; GLYCOPROTEIN ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY TITER; ANTIGEN DETECTION; ARTICLE; CELL ASSAY; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HERPES ZOSTER; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOREACTIVITY; INFECTION PREVENTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SKIN TEST; VARICELLA ZOSTER VIRUS;

ADULT; AGED; ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNITY, CELLULAR; INTERFERON-GAMMA; MALE; MIDDLE AGED; SKIN TESTS;

EID: 54249132503     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/592219     Document Type: Article

References (19)

1. Arvin AM. Varicella-zoster virus. Clin Microbiol Rev 1996; 9:361-81.
2. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004; 4:26-33.
3. Levin MJ, Barber D, Goldblatt E, et al. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis 1998; 178(Suppl 1):S109-12.
4. Berger R, Trannoy E, Hollander G, Bailleux F, Rudin C, Creusvaux H. A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. J Infect Dis 1998; 178(Suppl 1):S99-103.
5. Levin MJ, Smith JG, Kaufhold RM, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003; 188:1336-44.
6. Takahashi M, Okada S, Miyagawa H, et al. Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay. Vaccine 2003; 21:3845-53.
7. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84.
8. Hata A, Asanuma H, Rinki M, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002; 347:26-34.
9. Kamiya H, Ihara T, Hattori A, et al. Diagnostic skin test reactions with varicella virus antigen and clinical application of the test. J Infect Dis 1977; 136:784-8.
10. Baba K, Yabuuchi H, Okuni H, Takahashi M. Studies with live varicella vaccine and inactivated skin test antigen: protective effect of the vaccine and clinical application of the skin test. Pediatrics 1978; 61:550-5.
11. Smith JG, Liu X, Kaufhold RM, Clair J, Caulfield MJ. Development and validation of a gamma interferon ELISPOT assay for quantization of cellular immune responses to varicella-zoster virus. Clin Diagn Lab Immunol 2001; 8:871-9.
12. Smith JG, Levin M, Vessey R, et al. Measurement of cell-mediated immunity with a varicella-zoster virus-specific interferon-gamma ELISPOT assay: responses in an elderly population receiving a booster immunization. J Med Virol 2003; 70(Suppl 1):S38-41.
13. Chilmonczyk BA, Levin MJ, McDuffy R, Hayward AR. Characterization of the human newborn response to herpesvirus antigen. J Immunol 1985; 134:4184-8.
14. Hayward AR, Herberger M. Lymphocyte responses to varicella zoster virus in the elderly. J Clin Immunol 1987; 7:174-8.
15. Hayward AR, Zerbe GO, Levin MJ. Clinical application of responder cell frequency estimates with four years of follow up. J Immunol Methods 1994; 170:27-36.
16. Provost PJ, Krah DL, Kuter BJ, et al. Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine 1991; 9:111-6.
17. Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006; 145:317-25.
18. Gershon AA, Steinberg SP. Antibody responses to varicella-zoster virus and the role of antibody in host defense. Am J Med Sci 1981; 282:12-7.
19. Nagasawa K, Yamauchi Y, Tada Y, Kusaba T, Niho Y, Yoshikawa H. High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis. Ann Rheum Dis 1990; 49:630-3.